CLINICAL RESEARCH
Prevention and treatment of the toxic tumour syndrome following primary proton beam therapy of choroidal melanomas
1
Chair of Ophthalmology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
2
Department of Ophthalmology and Ocular Oncology, University Hospital, Krakow, Poland
Submission date: 2019-11-03
Final revision date: 2020-02-15
Acceptance date: 2020-02-16
Publication date: 2020-04-05
Arch Med Sci Civil Dis 2020;5(1):22-28
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The aim of this study was to evaluate the efficacy and safety of endoresection for choroidal melanoma to prevent and treat the toxic tumour syndrome (TTS).
Material and methods:
Thirteen patients who underwent primary proton beam therapy (PBRT) for choroidal melanoma followed by endoresection were evaluated. Main outcome measures were functional and anatomical results, surgical complications, rate of local recurrence, presence or absence of metastatic spread.
Results:
The median time of the follow-up period was 61.6 months. Six patients with clinical signs of TTS and seven with large tumours to prevent TTS underwent endoresection. Tumour thickness was 5.8 to 9.3 mm (mean: 7.6), the basal diameters were 10.6 to 15.0 mm (mean: 13.4). Preoperative best corrected visual acuity (BCVA) was 6/7.5 to counting fingers and the final BCVA was 6/15 to no light perception, and was better in those treated to prevent TTS (p = 0.01). The most universal early postoperative complication was bleeding from the scleral bed. The most common late postoperative complications were epiretinal membrane formation (30.8%), cystoid macular oedema (23.1%) and silicone oil-induced glaucoma (15.4%). Two (15.4%) patients developed phthisis bulbi, neither developed local recurrence. One patient developed liver metastases.
Conclusions:
Endoresection for choroidal melanoma is a safe and effective procedure with a high rate of local tumour control. The procedure appears to be useful in the prophylaxis and treatment of TTS after PBRT of choroidal melanoma.
The aim of this study was to evaluate the efficacy and safety of endoresection for choroidal melanoma to prevent and treat the toxic tumour syndrome (TTS).
Material and methods:
Thirteen patients who underwent primary proton beam therapy (PBRT) for choroidal melanoma followed by endoresection were evaluated. Main outcome measures were functional and anatomical results, surgical complications, rate of local recurrence, presence or absence of metastatic spread.
Results:
The median time of the follow-up period was 61.6 months. Six patients with clinical signs of TTS and seven with large tumours to prevent TTS underwent endoresection. Tumour thickness was 5.8 to 9.3 mm (mean: 7.6), the basal diameters were 10.6 to 15.0 mm (mean: 13.4). Preoperative best corrected visual acuity (BCVA) was 6/7.5 to counting fingers and the final BCVA was 6/15 to no light perception, and was better in those treated to prevent TTS (p = 0.01). The most universal early postoperative complication was bleeding from the scleral bed. The most common late postoperative complications were epiretinal membrane formation (30.8%), cystoid macular oedema (23.1%) and silicone oil-induced glaucoma (15.4%). Two (15.4%) patients developed phthisis bulbi, neither developed local recurrence. One patient developed liver metastases.
Conclusions:
Endoresection for choroidal melanoma is a safe and effective procedure with a high rate of local tumour control. The procedure appears to be useful in the prophylaxis and treatment of TTS after PBRT of choroidal melanoma.
REFERENCES (35)
1.
Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal N. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol 2017; 11: 279-89.
2.
Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine-125 barchytherapy for choroidal melanoma: V. Twelve year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol 2006; 124: 1684-93.
3.
Kowal J, Markiewicz A, Dębicka-Kumela M, Bogdali A, Romanowska-Dixon B. Outcomes of I-125 brachytherapy for uveal melanomas depending on irradiation dose applied to the tumor apex – a single institution study.
5.
Groenewald C, Konstantinidis L, Damato B. Effects of radiotherapy on uveal melanomas and adjacent tissues. Eye 2013; 27: 163-71.
6.
Seibel I, Cordini D, Willerding G, Riechardt AI, Joussen AM. Endodrainage, tumor photocoagulation, and silicone oil tamponade for primary exudative retinal detachment due to choroidal melanoma persisting after proton beam therapy. Ocul Oncol Pathol 2015; 1: 24-33.
7.
Hager A, Meissner F, Riechardt AI, et al. Breakdown of the blood-eye barrier in choroidal melanoma after proton beam radiotherapy. Graefes Arch Clin Exp Ophthalmol 2019; 257: 2323-28.
8.
Damato B. Vasculopathy after treatment of choroidal melanoma. In: Retinal Vascular Disease. Joussen AM, Gardner TW, Kirchhof B, Ryan SJ (eds). Springer, Berlin 2007; 582-91.
9.
Konstantinidis L, Groenewald C, Coupland SE, Damato B. Trans-scleral local resection of toxic choroidal melanoma after proton beam radiotherapy. Br J Ophthalmol 2014; 98: 775-9.
10.
McCannel TA. Post-brachytherapy tumor endoresection for treatment of toxic maculopathy in choroidal melanoma. Eye 2013; 27: 984-8.
11.
Cassoux N, Cayette S, Plancher C, et al. Choroidal melanoma: does endoresection prevent neovascular glaucoma in patient treated with proton beam irradiation? Retina 2013; 33: 1441-7.
12.
Seibel I, Riechard AI, Heufelder J, Joussen AM. Adjuvant ab interno tumor treatment after proton beam irradiation. Am J Ophthalmol 2017; 178: 94-100.
13.
Damato B, Groenewald C, McGalliard J, Wong D. Endoresection of choroidal melanoma. Br J Ophthalmol 1998; 82: 213-8.
14.
Kertes PJ, Johnson JC, Peyman GA. Internal resection of posteriori uveal melanomas. Br J Ophthalmol 1998; 82: 1147-53.
15.
Konstantinidis L, Groenewald C, Coupland S, Damato B. Long-term outcome of primary endoresection of choroidal melanoma. Br J Ophthalmol 2014; 98: 82-5.
16.
Modarres M, Rezanejad A, Falavariani KG. Recurrence and massive extraocular extention of choroidal malignant melanoma after vitrectomy and endoresection. Indian J Ophthalmol 2014; 62: 731-3.
17.
Chia SN, Smith HB, Hammer HM, Kemp EG. Incidence and indications for pars plana vitrectomy following the treatment of posterior uveal melanomas in Scotland. Eye (Lond) 2015; 29: 748-56.
18.
Garcia-Arumi J, Leila M, Zapata MA, et al. Endoresection technique with/without brachytherapy for management of high posterior choroidal melanoma; extended follow-up results. Retina 2015; 35: 628-37.
19.
Venkatesh P, Gogia V, Gupta S, Shah BM. 25 gauge endoresection for moderate to large choroidal melanoma. Indian J Surg Oncol 2016; 7: 365-67.
20.
Karkhaneh R, Chams H, Amoli FA, et al. Long-term surgical out-come of posterior choroidal melanoma treated by endoresection. Retina 2017; 27: 908-14.
21.
Vidoris AAC, Maia A, Lowen M, et al. Outcomes of primary endoresection for choroidal melanoma. Int J Retina Vitreous 2017; 3: 42.
22.
Peyman GA, Cohen SB. Ab interno resection of uveal melanoma. Int Ophthalmol 1986; 9: 29-36.
23.
Garcia-Arumi J, Sararols L, Martinez V, Corcostegui B. Vitreoretinal surgery and endoresection in high posterior choroidal melanomas. Retina 2001; 21: 445-52.
24.
Garcia-Arumi J, Zapata MA, Balaguer O, Fonollosa A, Boixadera A, Martinez-Castillo V. Endoresection in high posterior choroidal melanomas: long-term outcome. Br J Ophthalmol 2008; 92: 1040-5.
25.
Ferreyra HA, Goldbaum MH, Wenreb RN. Endoresection of irradiated choroidal melanoma as a treatment for intractable vitreous hemorrhage and secondary blood-induced glaucoma. Semin Ophthalmol 2008; 23: 135-8.
26.
Bechrakis NE, Foerster MH. Neoadjuvant proton beam radiotherapy combined with subsequent endoresection of choroidal melanomas. Int Ophthalmol Clin 2006; 46: 95-107.
27.
Damato B, Wong D, Green FD, Mackenzie JM. Intrascleral recurrence of uveal melanoma after transretinal “endoresection”. Br J Ophthalmol 2001; 85: 114-5.
28.
Biewald E, Lautner H, Gök M, et al. Endoresection of large uveal melanomas: clinical results in a consecutive series of 200 cases. Br J Ophthalmol 2017; 101: 204-8.
29.
Damato B, Groenwald C. Resection techniques. In: Clinical Ophthalmic Oncology. Uveal Tumors. Damato B, Singh AD (eds). Springer, Berlin 2014; 217-28.
30.
Süsskind D, Dürr C, Paulsen F, Kaulich T, Bartz-Schmidt KU. Endoresection with adjuvant ruthenium brachytherapy for selected uveal melanoma patients – the Tuebingen experience. Acta Ophthalmol 2017; 95: e727-33.
31.
Reichstein D, Karan K. Endoresection utilizing pars plana vitrectomy for benign and malignant intraocular tumors. Curr Opin Ophthalmol 2019; 30: 151-8.
32.
Mittica N, Vemuganti GK, Duffy M, Torczynski E, Edward DP. Late orbital recurrence of a choroidal melanoma following internal resection: report of a case and review of the literature. Surv Ophthalmol 2003; 48: 181-90.
33.
Mason JO, Mullins S. Pars plana vitrectomy associated with the following plaque brachytherapy for choroidal melanoma. In: Melanoma. From Early Detection to Treatment. Duc GHT (ed.). InTech, Rijeka 2013; 219-29.
34.
Hadden PW, Hiscott PS, Damato BE. Histopathology of eyes enucleated after endoresection of choroidal melanoma. Ophthalmology 2004; 111: 154-60.
35.
Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol 2017; 101: 38-44.
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
